GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ovation Science Inc (XCNQ:OVAT) » Definitions » COGS-to-Revenue

Ovation Science (XCNQ:OVAT) COGS-to-Revenue : 0.02 (As of Jun. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Ovation Science COGS-to-Revenue?

Ovation Science's Cost of Goods Sold for the three months ended in Jun. 2024 was C$0.00 Mil. Its Revenue for the three months ended in Jun. 2024 was C$0.04 Mil.

Ovation Science's COGS to Revenue for the three months ended in Jun. 2024 was 0.02.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Ovation Science's Gross Margin % for the three months ended in Jun. 2024 was 97.62%.


Ovation Science COGS-to-Revenue Historical Data

The historical data trend for Ovation Science's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ovation Science COGS-to-Revenue Chart

Ovation Science Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial 0.06 0.27 0.16 0.02 0.13

Ovation Science Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.50 0.25 0.33 0.50 0.02

Ovation Science COGS-to-Revenue Calculation

Ovation Science's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.008 / 0.062
=0.13

Ovation Science's COGS to Revenue for the quarter that ended in Jun. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.001 / 0.042
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ovation Science  (XCNQ:OVAT) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Ovation Science's Gross Margin % for the three months ended in Jun. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0.001 / 0.042
=97.62 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Ovation Science COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Ovation Science's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Ovation Science Business Description

Traded in Other Exchanges
Address
625 Howe Street, Suite 1140, Vancouver, BC, CAN, V6C 2T6
Ovation Science Inc is a Canada-based company mainly engaged in the business of sub-licensing rights to use Invisicare, a patented drug delivery technology used in topical and transdermal skin products containing hemp seed oil and cannabis products. The company also holds the right to manufacture, distribute, sell, market, sub-license and promote products formulated with Invisicare and containing cannabis products including cannabinoids, hemp seed oil and any synthetic derivatives of cannabis. It also develops formulas for skin product lines including topical and transdermal creams and lotions containing hemp seed oil and cannabis.
Executives
David K. Ryan Director

Ovation Science Headlines

No Headlines